Repligen (RGEN)
(Real Time Quote from BATS)
$142.64 USD
-3.14 (-2.15%)
Updated Jun 10, 2024 03:06 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 141 - 160 ( 205 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Overweight - The ''Cinderella of Bioprocessing''
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Steady as a Rock; Robust 2Q20 Results; Raising PT to $168
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
EMT Acquisition Provides Tuck-in Value; Reiterate Buy; Raising PT to $151
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Financials Reported; Trucking Blithely Onward; Raising PT to $143
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department